MEGHALAYAN MEDICAL DRUGS & SERVICES LIMITED
A Govt. of Meghalaya Undertaking
सत्यमेव जयते
Government of Meghalaya
Meghalayan Medical Drugs & Services Ltd
Pasteur Hills, Lawmali Road,
Next to MECL,
Shillong 793001
+91-9863033404 / 9863048955
contactdesk@mmdsl.in

No. MMDSL/1/pro/med/Equipment/2024(255) Dated: 03/11/2026

CORRINGENDUM/ADDENDUM

Reference to the Short Notice Inviting Tender No. MMDSL/1/pro/med/Equipment/2024(237) Dated: 22/09/2026 **for supply of Mould Room And Patient Immobilization Accessories, HPV Test Kit For Project Titled Automated Molecular Diagnostic System And ECG Machine** the following corrigendum to the queries raised are hereby notified through this to all concerned based.

Serial No.	Tender/Clause No	Item/Clause/Query	Corrigendum/Addendum
1	Item No. 2 – HPV Test Kit for Automated Molecular Diagnostic System	The item description refers to HPV test kits, but the technical specifications also refer to an instrument/system, installation, commissioning, validation and training. Kindly clarify whether the bidder must supply only HPV test kits and consumables for an existing compatible machine, or the complete automated molecular diagnostic system along with kits and accessories.	The successful bidder shall supply the complete automated molecular diagnostic system, HPV test kits and necessary accessories. The institution will provide a bare room; the bidder will be responsible for site assessment and preparation, transportation, installation, commissioning, validation, training, maintenance, servicing and other requirements for proper operation. All associated costs must be included in the quoted test-kit price, with no additional payment by the institution.
2	Item No. 3 – Portable 12-Channel ECG Machine	Kindly confirm whether an equivalent make and model of portable 12-channel ECG machine may be quoted, provided it meets the required technical specifications and functional requirements.	Equivalent make/model is permitted, provided the offered machine meets the tender's technical and functional requirements.
3	HPV Test Kit – Rate Contract	The specifications mention a three-year rate contract, extendable by a further two years, but the item schedule does not clearly indicate the required quantity. Kindly clarify the estimated annual quantity and total quantity for the contract period.	The first-year estimated requirement is 10,000 tests. Quantities for subsequent years and any extension depend on fund availability and Ministry approval; no future quantity is guaranteed.
4	HPV Test Kit – 400 Free Tests	The specifications require a minimum of 400 tests free of cost for installation, commissioning, validation, training and trial testing. Kindly clarify whether these 400 tests are separate from the routine purchase quantity and whether the requirement applies to every bidder or only the successful bidder.	The successful bidder shall provide a minimum of 400 tests free of cost, without controls/calibrators, irrespective of pack size. Remaining tests may be counted as commercial tests.
5	HPV System – Compatibility and Installation	Kindly confirm the location and existing infrastructure of the proposed installation site, including whether the necessary machine, computer, software, utilities and other infrastructure are already available or must be supplied under this tender.	The supplier's complete installation and operating responsibilities, and inclusion of related costs in the quoted test-kit price, were confirmed.
6	Mould Room and Patient Immobilization Accessories	The specifications state that vendors should include any additional items required for smooth operation and quote their rates. Kindly clarify whether these additional items are mandatory, how they will be evaluated, and whether they will be ordered only with prior approval by MMDSL.	MMDSL may decide whether to procure any of the additional items based on its requirements. The rates quoted for such items may be considered for future procurement, if required. Quoting additional items shall not constitute a commitment by MMDSL to purchase them.
7	Warranty and Maintenance	The equipment warranty section specifies a three-year warranty, repair response within 24 hours, replacement if repairs cannot be completed within that timeframe, preventive maintenance and on-site corrective maintenance. Kindly clarify the applicable service location, whether the 24-hour period means	The warranty period shall be three (3) years. The service response time shall be applicable as per the location and category of the healthcare facility, as specified below: District Hospitals (DHs): Within 24 hours.

Approved By Shri Ramkumar S(Managing Director) on November 3, 2026 08:46 AM IST
(The document is digitally approved and does not require any Seal or Signature in original)

Meghalayan Medical Drugs & Services Ltd
Pasteur Hills, Lawmali Road,
Next to MECL,
Shillong 793001
+91-9863033404 / 9863048955
contactdesk@mmdsl.in

Approved By Shri Ramkumar S(Managing Director) on November 3, 2026 08:46 AM IST
(The document is digitally approved and does not require any Seal or Signature in original)

		response or resolution, and how the replacement requirement will be applied.	Community Health Centres (CHCs): Within 2 days. Primary Health Centres (PHCs): Within 3 days. The specified timeframes refer to the service response time and not necessarily the time required to complete the repair. The supplier shall provide preventive maintenance and on-site corrective maintenance during the warranty period. If the equipment cannot be repaired within the applicable timeframe, the supplier shall arrange for its replacement in accordance with the tender conditions.
8	Clarification Regarding Procurement Model of the Instrument	The tender document does not clearly specify whether the Automated Molecular Diagnostic System is proposed to be procured through: • Outright Purchase, or • Reagent Rental Placement (RRP) Model. In case the intended procurement model is RRP/Reagent Rental Placement, the tender document does not mention the anticipated annual test volume or minimum committed test consumption. This information is essential for bidders to arrive at a realistic and competitive commercial proposal. We therefore request MMDSL to clarify the procurement model and specify the estimated annual testing requirements.	The instrument is to be provided and installed by the successful bidder under the project arrangement. The currently funded first-year quantity is 10,000 tests; future quantities depend on funding and Ministry approval.
9	2. Technical Specifications for HPV Test Kits for Automated Molecular Diagnostic System Sl. No. 1: Automated Molecular Diagnostic System	Existing Specification: The offered system should be fully automated and integrated, covering end-to-end HPV DNA detection, including sample preparation, automated nucleic acid extraction, amplification, detection, and result interpretation for HPV 16, HPV 18, and other high-risk genotypes in a single tube. Modification Requested: The offered system should be fully automated and integrated, covering end-to-end HPV DNA detection, including sample preparation, automated nucleic acid extraction, amplification, detection, and result interpretation for HPV 16, HPV 18, and other high-risk genotypes in a single and/or multiple tube format. Justification: The requirement of a single-tube format is highly restrictive and may inadvertently favor a particular manufacturer. Multiple internationally validated HPV testing platforms employ different assay designs while maintaining equivalent clinical performance, sensitivity, specificity, and regulatory compliance. Broadening this criterion will encourage wider participation without compromising quality.	The Single-tube PCR processing requirement retained. Detailed SOP must cover sample collection, handling and transport, pre-analytical requirements, sample loading and processing, manual interventions, consumables, processing conditions and timing, and final result interpretation.
10	Sl. No. 9: Free Kits for Trial & Installation	Existing Specification: The successful bidder shall supply a minimum of 400 tests free of cost for installation, commissioning, validation, training, and trial testing of the instrument. Modification Requested: The successful bidder shall supply a minimum of 380 tests free of cost for installation, commissioning, validation, training, and trial testing of the instrument. Justification: The existing requirement appears aligned with a particular pack configuration and may favor specific manufacturers. A requirement of 380 tests would	The successful bidder shall provide at least 400 tests free of cost, without controls/calibrators, regardless of pack size. Remaining tests may be counted as commercial tests.

Meghalayan Medical Drugs & Services Ltd
Pasteur Hills, Lawmali Road,
Next to MECL,
Shillong 793001
+91-9863033404 / 9863048955
contactdesk@mmdsl.in

Approved By Shri Ramkumar S(Managing Director) on November 3, 2026 08:46 AM IST
(The document is digitally approved and does not require any Seal or Signature in original)

		accommodate different pack sizes while adequately supporting installation, validation, and training activities.	
11	Sl. No. 19: Contamination Control Features	Existing Specification: The system should operate in a single room with integrated contamination prevention features such as dedicated pipette tips with filters, automatic sealing of amplification plates, enclosed reaction areas, and inbuilt Uracil-N-Glycosylase (UNG)/similar contamination control included in the main kit, requiring no additional preparation. Modification Requested: The system should operate in a single room with integrated contamination prevention features such as dedicated pipette tips with filters, automatic sealing of amplification plates, enclosed reaction areas, and equivalent validated contamination-control mechanisms. Justification: The requirement for a specific contamination-control chemistry may unintentionally favor a particular manufacturer. Several internationally approved molecular diagnostic systems utilize alternative and equally effective contamination-prevention methodologies. Therefore, equivalent contamination-control approaches should also be accepted.	Retain the requirement and allow equivalent validated methods subject to supporting evidence and technical evaluation.
12	Sl. No. 27: Instrument Functions and Requirements	Existing Specification: The system should be capable of handling a high throughput of ≥120 samples within 8 hours and should have a continuous sample loading feature for optimal laboratory efficiency and automation. Modification Requested: The system should be capable of handling a high throughput of ≥90 samples within 8 hours and should have a continuous batch loading feature for optimal laboratory efficiency and automation. Justification: The specified throughput of 120 samples within 8 hours appears highly restrictive and may limit competition. A throughput of 90 samples within 8 hours is adequate for effective cervical cancer screening programs while allowing participation from a broader range of technically qualified systems.	The request to reduce throughput to 90 samples was not accepted.
13	Sl. No. 28: Proven Credibility in Government Setups in India	Existing Specification: The quoted model (or equivalent models) should be present in India at least at five (5) premier government institutes for more than 1–2 years, and the bidder/OEM should include relevant documentary proof. Modification Requested: The quoted model (or equivalent models) should be present in India at least at two (2) premier government institutes for more than 1 years, and the bidder/OEM should include relevant documentary proof. Justification: Globally established manufacturers possessing robust regulatory approvals, proven clinical performance, and international installations may not necessarily have five installations in premier government institutions within India. Reducing this	The quoted model (or equivalent models) should be present in India at least at 3 premier government institutes in India for more than 1-2 years and each institution's performed at least 10,000 HPV screening.The bidder/OEM should include relevant documentary evidence.

Meghalayan Medical Drugs & Services Ltd
Pasteur Hills, Lawmali Road,
Next to MECL,
Shillong 793001
+91-9863033404 / 9863048955
contactdesk@mmdsl.in

Approved By Shri Ramkumar S(Managing Director) on November 3, 2026 08:46 AM IST
(The document is digitally approved and does not require any Seal or Signature in original)

		requirement to two installations would improve competition while maintaining credibility and performance standards.	
14	Sl. No. 29: Preferable Comprehensive Solution for All Molecular Needs	Existing Specification: The offered system should be capable of performing additional molecular assays/parameters such as HIV-VL, HBV-VL, HCV-VL, CMV, EBV, BKV, CT/NG, MTB RIF/INH, and NAT for blood screening. Modification Requested: Request for deletion of this specification. Justification: The current tender is specifically intended for HPV testing under a cervical cancer screening program. The inclusion of multiple unrelated assays is beyond the scope of the present procurement and may unnecessarily favor a specific platform. Evaluation should be based primarily on the ability of the offered system to effectively perform HPV testing as required under the project.	No amendment to this specification was required.
15	Clarification regarding procurement model of the instrument	The tender document does not clearly specify whether the Automated Molecular Diagnostic System is intended to be procured through outright purchase or whether the instrument is to be deployed under an RRP/Reagent Rental Placement model. If the intended procurement model is RRP/Reagent Rental Placement, the minimum committed/estimated test consumption or annual test volume has not been specified in the tender document.	The instrument is to be provided and installed by the successful bidder under the project arrangement. The currently funded first-year quantity is 10,000 tests; future quantities depend on funding and Ministry approval.
16	Specifications SL No. 1 Automated Molecular Diagnostic System	Existing Specification: The offered system should be fully automated and integrated, covering end-to-end HPV DNA detection, including sample preparation, automated nucleic acid extraction, amplification, detection, and result interpretation for HPV 16, HPV 18, and other high-risk genotypes in a single tube. Modification requested: The offered system should be fully automated and integrated, covering end-to-end HPV DNA detection, including sample preparation, automated nucleic acid extraction, amplification, detection, and result interpretation for HPV 16, HPV 18, and other high-risk genotypes in a single/multiple tube. Justification for Our Request: This point is biased and favors one company.	The detailed SOP must cover sample collection, handling and transport, pre-analytical requirements, sample loading and processing, manual interventions, consumables, processing conditions and timing, and final result interpretation.
17	Specifications SL No. 9 Free Kits for Trial & Installation	Existing Specification: The successful bidder shall supply a minimum of 400 tests free of cost for installation, commissioning, validation, training and trial testing of the instrument. Modification requested: The successful bidder shall supply a minimum of 380 tests free cost for installation, commissioning, validation, training and trial testing of the instrument. Justification for Our Request: The Pack size favors one company.	The successful bidder shall provide at least 400 tests free of cost, without controls/calibrators, regardless of pack size. Remaining tests may be counted as commercial tests.
18	Specifications SL No. 19: Contamination Control Features	Existing Specification: The system should operate in a single room with integrated contamination prevention features such as dedicated pipette tips with filters, automatic sealing of amplification plates, enclosed reaction areas, and inbuilt Uracil-N-Glycosylase (UNG)/ Similar Contamination control included in the main kit, requiring no additional	Retain the requirement and allow equivalent validated methods subject to supporting evidence and technical evaluation.

Meghalayan Medical Drugs & Services Ltd
Pasteur Hills, Lawmali Road,
Next to MECL,
Shillong 793001
+91-9863033404 / 9863048955
contactdesk@mmdsl.in

Approved By Shri Ramkumar S(Managing Director) on November 3, 2026 08:46 AM IST
(The document is digitally approved and does not require any Seal or Signature in original)

		preparation. Modification requested: The system should operate in a single room with integrated contamination prevention features such as dedicated pipette tips with filters, automatic sealing of amplification plates, enclosed reaction areas. Justification for Our Request: The contamination control reagent is specific to one company. There are other internationally approved contamination control reagents also available.	
19	Specifications SL No. 27: Instrument Functions and Requirements (Point no 2)	Existing Specification: The system should be capable of handling a high throughput of ≥120 samples within 8 hours and should have a continuous sample loading feature for optimal laboratory efficiency and automation. Modification requested: The system should be capable of handling a high throughput of ≥ 90 samples within 8 hours and should have a continuous batch loading feature for optimal laboratory efficiency and automation. Justification for Our Request: The throughput favouring a particular company.	The request to reduce throughput to 90 samples was not accepted.
20	Specifications SL No. 28: Proven Credibility in Government setups in India	Existing Specification: The quoted model (or equivalent models) should be present in India at least at five (5) premier government institutes for more than 1–2 years, and the bidder/OEM should include relevant documentary proof. Modification requested: The quoted model (or equivalent models) should be present in India at least at Two (2) premier government institutes for more than 1–2 years, and the bidder/OEM should include relevant documentary proof. Justification for Our Request: Manufacturers with established international experience, appropriate regulatory approvals, and satisfactory clinical performance may not necessarily have five installations in premier Government institutions in India.	The quoted model (or equivalent models) should be present in India at least at 3 premier government institutes in India for more than 1-2 years and each institution's performed at least 10,000 HPV screening.The bidder/OEM should include relevant documentary evidence.
21	Specifications SL No. 29: Preferable Comprehensive Solution for All Molecular Needs	Existing Specification: The offered system should be capable of performing additional molecular assays/parameters such as HIV-VL, HBV-VL, HCV-VL, CMV, EBV, BKV CT/NG, MTB RIF/INH, and NAT for blood screening. Modification requested: Remove specification Justification for Our Request: As the present project is specifically intended for HPV testing/cervical cancer screening, we request that this should be removed. All the assays mentioned favouring to one company.	No amendment to this specification was required.

The last date and time for submission of bids shall be 11:30 AM on 5th November 2026, and the date and time of opening of the tender shall be 2:30 PM on 5th November 2026. All other terms and conditions of the original tender shall remain unchanged.

Place of Submission: Meghalayan Medical Drugs & Services Ltd, Pasteur Hills, Lawmali Road, Next to MECL, Shillong 793001

Meghalayan Medical Drugs & Services Ltd
Pasteur Hills, Lawmali Road,
Next to MECL,
Shillong 793001
+91-9863033404 / 9863048955
contactdesk@mmdsl.in

Shri Ramkumar S
Managing Director

Copy to: 1. The Tender Committee MMDSL.

Approved By Shri Ramkumar S(Managing Director) on November 3, 2026 08:46 AM IST
(The document is digitally approved and does not require any Seal or Signature in original)